Product Information
MIGRAINE 250-250-65 MG GELTAB is a generic product labeled by Cardinal Health, priced at $0.0648 per EA under NDC 70000061101. Its NADAC has been published 192 times since Feb 1, 2023.
FDA first approved this application on Nov 26, 2001.
Strength
250; 250; 65 mg/1; mg/1; mg/1
Manufacturer
Cardinal HealthNDC
70000061101
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; ASPIRIN; CAFFEINEApproval Type
Generic (ANDA)
FDA Application
ANDA075794FDA Approved
11/26/2001
On Market Since
8/8/2022
Pharmacological Classes
Price Statistics
The NADAC for MIGRAINE 250-250-65 MG GELTAB has been published 192 times since Feb 1, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0648 per EA |
|---|---|
| All-time high | $0.0698 (Sep 11, 2024) |
| All-time low | $0.0584 (Apr 17, 2024) |
| 52-week high | $0.0691 |
| 52-week low | $0.0635 |
| Median price | $0.0646 |
| Average price | $0.0642 |
| Largest weekly change | +11.2% (Oct 18, 2023) |
| Weeks tracked | 192 |
| Tracking since | Feb 1, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the acetaminophen, aspirin, caffeine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cardinal Health manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
acetaminophen, aspirin, caffeine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MIGRAINE 250-250-65 MG GELTAB?
The current National Average Drug Acquisition Cost (NADAC) for MIGRAINE 250-250-65 MG GELTAB, manufactured by Cardinal Health, is $0.0648 per EA (NDC 70000061101), effective Sep 30, 2026.
How has the price of MIGRAINE 250-250-65 MG GELTAB changed over time?
Over the history we have for it, the NADAC for MIGRAINE 250-250-65 MG GELTAB has held within roughly two percent of its current level. It has been tracked across 192 weekly CMS publications since Feb 1, 2023.
What are the highest and lowest recorded NADAC prices for MIGRAINE 250-250-65 MG GELTAB?
Since Feb 1, 2023, the NADAC for MIGRAINE 250-250-65 MG GELTAB has ranged from a low of $0.0584 (Apr 17, 2024) to a high of $0.0698 (Sep 11, 2024), with a median of $0.0646 per EA.
Are there cheaper alternatives to MIGRAINE 250-250-65 MG GELTAB?
No other NADAC-published product currently shares the active ingredient and strength of MIGRAINE 250-250-65 MG GELTAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MIGRAINE 250-250-65 MG GELTAB?
MIGRAINE 250-250-65 MG GELTAB (NDC 70000061101) is labeled by Cardinal Health, and CMS classifies it as a generic product.